9:00 am Registration & Coffee

9:20 am Chair’s Opening Remark

• Jeffrey Pollard Director, Professor of Resilience Biology, Medical Research Council Centre for Reproductive Health, University of Edinburgh

Advancing Development of Next Generation Cancer Immunotherapy by Optimizing Clinical Development of CD47/SIRPα Targeted Macrophage Therapies

9:30 am Industry Leader’s Fireside Chat

• Yaron Pereg Chief Executive Officer, Kahr Medical
• Nicolas Poirier Chief Scientific Officer, OSE Immunotherapeutics
• Yang Liu Founder, President and Chief Scientific Officer , Oncoimmune

10:00 am AO-176, a highly differentiated CD47-targeting antibody for the treatment of cancers

• Arun Kashyap Vice President, Research , Arch Oncology

10:30 am Using a SIRPα & other new Don’t Eat Me Targeted Myeloid Checkpoint Inhibitor to Develop Safe & Efficacious Treatment for Solid Tumors

• Nicolas Poirier Chief Scientific Officer, OSE Immunotherapeutics

11:00 am Development of a macrocyclic peptide that blocks the CD47-SIRPα interaction as a new cancer immunotherapy

• Takashi Matozaki Professor, Kobe University Graduate School of Medicine

11:30 am The Use of In Vitro Macrophage Assays to Accelerate IO Drug Development

• Thibaut Janss Senior Scientist, ImmunXperts, a Nexelis Group Company

11:45 am Morning Refreshments & Speed Networking

Advancing Development of Next Generation Cancer Immunotherapy by Optimizing Clinical Development of CD47/SIRPα Targeted Macrophage Therapies

12:15 pm DSP107 – A First-In-Class Bi-Functional CD47x41BB Targeting Compound

• Yaron Pereg Chief Executive Officer, Kahr Medical

12:45 pm Targeting Tumor-associated Macrophages using Self-assembled Supramolecule

• Ashish Kulkarni Assistant Professor of Chemical Engineering , University of Massachusetts Amherst

1:15 pm TTI-621 and TTI-622 target the CD47 “do not eat” signal on tumor cells

• Gloria Lin Associate Director of Translational Research , Trillium Therapeutics Inc.

Looking Beyond CD47: Exploring Novel Pathways & Proteins to Cement The Future of Macrophage Targeted Therapies

1:45 pm Lunch & Networking

2:45 pm Determining The Potential Of Utilizing CD24 Blockade For Anti-Tumor Treatment

• Yang Liu Founder, President and Chief Scientific Officer , Oncoimmune

3:15 pm Macrophage Scavenger Receptors as Targets for Anti-Tumor Immunity

• Juho Jalkanen Chief Development Officer , Faron Pharmaceuticals

3:45 pm Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis

• Bruce C. Trapnell Professor of Medicine and Pediatrics, Director, University of Cincinnati College of Medicine, Translational Pulmonary Science Center, Cincinnati Children’s Hospital

4:15 pm Afternoon Refreshments & Poster Session

5:45 pm Chairman’s Closing Remarks

6:00 pm Close of Day 1